Incannex Healthcare (NASDAQ:IXHL – Get Free Report) and TFF Pharmaceuticals (NASDAQ:TFFP – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.
Risk and Volatility
Incannex Healthcare has a beta of 7.68, suggesting that its stock price is 668% more volatile than the S&P 500. Comparatively, TFF Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.
Valuation and Earnings
This table compares Incannex Healthcare and TFF Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Incannex Healthcare | $10,000.00 | 2,945.35 | -$18.46 million | ($1.39) | -1.20 |
| TFF Pharmaceuticals | $730,000.00 | 1.87 | -$21.24 million | ($6.44) | -0.05 |
Profitability
This table compares Incannex Healthcare and TFF Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Incannex Healthcare | N/A | -182.23% | -127.38% |
| TFF Pharmaceuticals | -1,596.64% | -310.17% | -196.06% |
Insider and Institutional Ownership
0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 15.3% of TFF Pharmaceuticals shares are held by institutional investors. 26.5% of Incannex Healthcare shares are held by insiders. Comparatively, 4.5% of TFF Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Incannex Healthcare and TFF Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Incannex Healthcare | 0 | 0 | 0 | 0 | 0.00 |
| TFF Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
TFF Pharmaceuticals has a consensus target price of $44.00, suggesting a potential upside of 14,185.71%. Given TFF Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe TFF Pharmaceuticals is more favorable than Incannex Healthcare.
Summary
Incannex Healthcare beats TFF Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Incannex Healthcare
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
